Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

An ADR is created when a bank buys shares of a foreign company outside the United States and issues a security representing shares of that company. Priced in U.S. dollars, these ADR shares trade just ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...